{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006951","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.101716+00:00","generated_at":"2026-06-08T06:26:18.154726+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arbutus and Barinthus report preliminary Phase 2a data: imdusiran + VTP-300 sustains low HBsAg levels in cHBV","bullets":["Preliminary data from AB-729-202 trial: 97% of imdusiran-treated pts had HBsAg <100 IU/mL at first VTP-300 dose.","Mean HBsAg reduction of -1.86 log10 after 24 weeks of imdusiran; all VTP-300 patients maintained <100 IU/mL through week 48.","60% of VTP-300 patients had HBsAg <10 IU/mL through week 48; all qualified to stop NA therapy.","HBV-specific T cell IFN-γ production enhanced vs placebo; no serious AEs, Grade 3/4 AEs, or discontinuations.","Updated corporate presentation posted on company website with additional pipeline details."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006951","json":"https://secwatch.observer/filing/0001171843-23-006951.json","markdown":"https://secwatch.observer/filing/0001171843-23-006951.md","text":"https://secwatch.observer/filing/0001171843-23-006951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006951/0001171843-23-006951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006951/f8k_110923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:26:18.154726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}